The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

Metastatic castration-resistant prostate cancer (mCRPC) is a severe form of late-stage disease where the tumor can no longer ...

According to Vesprini, the most common problem most men experience is that the prostate continues growing. While it might be ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies, other ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds.

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from drug or hormonal therapies ...

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing ...

The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive prostate cancer could unlock a sizeable new market for the drug.

Hearing the news that you have a tumour which could shorten your life is something we all dread. But there may be an ...

The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis, as well as prognostic and predictive biomarkers, may further ...

Current injectable drugs in the class include leuprorelin, triptorelin, goserelin, and buserelin, and people men with advanced hormone-sensitive prostate cancer are normally offered ADT with these ...